Jinwon Life Sciences VGXI Participates in World Vaccine Conference... Selected as Finalist for Excellence Award

Jinwon Life Sciences announced on the 16th that its subsidiary VGXI, a high-quality plasmid DNA contract development and manufacturing organization (CDMO) company, will participate in the World Vaccine Congress.

The World Vaccine Congress is the largest and most prestigious event in the vaccine industry, where scientists, companies, and academia from the global pharmaceutical and biotech sectors gather to share knowledge and seek collaboration on the latest vaccine science, technology, and supply. It will be held from April 3 to 6 in Washington DC, USA.

Additionally, the event includes the Vaccine Industry Excellence Awards, which annually recognize companies and research teams that have demonstrated outstanding achievements and contributions in the vaccine industry, selected through votes from vaccine researchers and experts worldwide.

This year’s event will see the attendance of government officials from agencies such as the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC), as well as key executives from multinational pharmaceutical companies including Moderna’s Chief Medical Officer, Merck, Pfizer, Sanofi, and Janssen.

Park Young-geun, CEO of Jinwon Life Sciences, stated, “By participating in an event attended by over 3,000 key stakeholders from the global vaccine industry and pharmaceutical companies, we will highlight VGXI’s business competitiveness as a contract manufacturing partner providing high-quality plasmid DNA production capabilities strengthened by the completion of our new factory and excellent customer-tailored services.” He added, “We plan to actively engage in networking to raise our recognition in the global biopharmaceutical industry and maximize sales performance by discussing business partnerships with potential clients.”

He continued, “VGXI is a finalist for the Vaccine Industry Excellence Award in the Production/Process Development category hosted by this year’s World Vaccine Congress,” and said, “Having already won several awards including the Best Contract Manufacturing Award by surpassing strong competitors, we expect good results again this year.”